hh.sePublications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Cost of illness from the public payers' perspective in patients with ankylosing spondylitis in rheumatological care
Musculoskeletal Sciences, Department of Orthopedics, Lund University Hospital, Klinikgatan 22, SE-221 85 Lund, Sweden.
Musculoskeletal Sciences, Department of Orthopedics, Lund University Hospital, Klinikgatan 22, SE-221 85 Lund, Sweden.
Research and Development Centre, Spenshult Hospital for Rheumatic Diseases, Halmstad, Sweden.
Department of Rheumatology, Skåne University Hospital, Lund University, Lund, Sweden.
Show others and affiliations
2010 (English)In: Journal of Rheumatology, ISSN 0315-162X, E-ISSN 1499-2752, Vol. 37, no 11, 2348-55 p.Article in journal (Refereed) Published
Abstract [en]

OBJECTIVE: To estimate the incremental costs to public payers for patients with ankylosing spondylitis (AS) of working age compared with reference subjects from the general population.

METHODS: We investigated total costs for 3 years (2005-2007) in 116 outpatients under 66 years of age with AS attending rheumatological care in Malmö, Sweden. Mean (SD) age was 46 (11) years and mean (SD) disease duration was 24 (11) years. Two subjects per AS patient matched for age, sex, and residential area were selected from the Population Register to serve as a reference group. We retrieved data concerning sick leave, prescription drugs, and healthcare consumption from Swedish health-cost registers by the unique personal identification numbers.

RESULTS: The mean total cost for the 3-year period 2005-2007 was US $37,095 (SD $30,091) for patients with AS, and $11,071 (SD $22,340) for the reference group. The mean indirect cost was $19,618 and $5905, respectively. Mean cost for healthcare was $8998 for the AS patients and $4187 for the reference subjects, and mean cost for drugs was $8479 and $979, respectively. The patients with AS treated with biological therapy constituted 80% of the total drug cost, but just 40% of the cost for disability pension.

CONCLUSION: Patients with AS had 3-fold increase in costs compared to reference subjects from the general population, and the drug costs were almost 10 times as high. Production losses (indirect cost) represented more than half of total cost (53%).

Place, publisher, year, edition, pages
2010. Vol. 37, no 11, 2348-55 p.
National Category
Medical and Health Sciences
Identifiers
URN: urn:nbn:se:hh:diva-22242DOI: 10.3899/jrheum.100099PubMedID: 20716657OAI: oai:DiVA.org:hh-22242DiVA: diva2:622419
Available from: 2013-05-21 Created: 2013-05-21 Last updated: 2017-06-20Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Bremander, Ann
In the same journal
Journal of Rheumatology
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar

Altmetric score

Total: 47 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf